Drug Trial Radar · NCT06454708
Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects
Last checked: Nov 20, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 1, 2024
Primary completion
Aug 12, 2024
Study completion Aug 12, 2024
Sponsor
- Lead sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the pharmacokinetics (PK) of Clascoterone Cream, 1% after single dose and repeat dose topical administrations in healthy Chinese adult subjects.
Conditions
- Acne Vulgaris
Interventions
Clascoterone Cream 1%Drug
Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to maximum plasma concentration (Tmax)Time frame: Day 1
- Maximum plasma concentration (Cmax)Time frame: Day 1
- Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration (AUC0-t)Time frame: Day 1
- Time to maximum plasma concentration (Tmax)Time frame: Day 7
- Maximum plasma concentration at steady state (Cmax,ss)Time frame: Day 7
- Minimum plasma concentration at steady state (Cmin,ss)Time frame: Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
London, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.